Previous 10 | Next 10 |
CONSHOHOCKEN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Goldman Sachs 45 th Annual Global Healthcare Conference on Tuesday, June 11, 2024, and will present at 8:40 A.M. ET. The presentati...
2024-06-04 15:40:11 ET More on Viking Therapeutics What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired Viking Therapeutics, Inc. (VKTX) Q1 2024 Earnings Call Transcrip...
2024-05-31 15:00:19 ET More on the markets Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight Hedge funds back at record exposure to Magnificent 7 S&am...
2024-05-29 11:00:21 ET Yasmeen Rahimi from Piper Sandler issued a price target of $336.00 for MDGL on 2024-05-29 09:13:00. The adjusted price target was set to $336.00. At the time of the announcement, MDGL was trading at $221.755. The overall price target consensus is a...
CONSHOHOCKEN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced ten data presentations at the upcoming European Association for the Study...
2024-05-28 17:45:19 ET Summary Today, we take a more in-depth look at Altimmune, Inc., a biotechnology company focused on developing therapies for obesity and liver disease. The company's key asset is pemvidutide, a GLP-1 agonist that has shown some potentially promising results i...
2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...
2024-05-21 09:45:00 ET Madrigal Pharmaceuticals ' (NASDAQ: MDGL) shares are down by 27% over the past year, while the S&P 500 is up by 26%. However, this poor performance hardly reflects the progress the biotech has made. Madrigal recently earned regulatory approval for Rezd...
2024-05-16 08:21:28 ET Paulson & Co., the hedge fund founded by John Paulson, increased its stakes in NovaGold ( NG ) to 27.24M from 23.54M shares, International Tower Hill Mines ( THM ) to 64.2M from 61.93M shares and Madrigal Pharmaceuticals (NASDAQ:MDGL) during Q1, accordin...
2024-05-07 11:56:08 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Madrigal Pharmaceuticals (NASDAQ: MDGL ) just reported results for the first quarter of 2024. Madrigal Pharmaceuticals reported earnings per share of -$7.38. This was belo...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...
2024-06-15 09:45:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is in a position that most other biotechs envy. Its first medicine just hit the market, sales are due to start rolling in, and there aren't any other companies that can slow it down -- for now, that is. By mid-2027, ...